Media coverage about Juno Therapeutics (NASDAQ:JUNO) has trended somewhat positive on Thursday, according to Accern. The research firm identifies positive and negative news coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Juno Therapeutics earned a news sentiment score of 0.14 on Accern’s scale. Accern also assigned news stories about the biopharmaceutical company an impact score of 44.7983313885835 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Juno Therapeutics opened at $86.96 on Thursday, MarketBeat.com reports. Juno Therapeutics has a twelve month low of $19.62 and a twelve month high of $87.01. The company has a quick ratio of 4.77, a current ratio of 3.61 and a debt-to-equity ratio of 0.01.
About Juno Therapeutics
Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.
Receive News & Ratings for Juno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.